Jiangsu Jibeier Pharmaceutical (688566) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 201.80 million, up 3.90% year-over-year, while net profit attributable to shareholders declined 5.68% to RMB 49.53 million.

• Basic and diluted EPS were RMB 0.25, down 10.71% from the same period last year.

Financial highlights

• Operating cash flow dropped 46.29% year-over-year to RMB 43.99 million, mainly due to reduced bank acceptance bill discounting.

• R&D investment increased 64.28% to RMB 15.93 million, representing 7.89% of revenue.

• Total assets at quarter-end were RMB 2.55 billion, up 0.87% from year-end 2024.

• Shareholders' equity rose 2.20% to RMB 2.30 billion.

Key financial ratios and metrics

• Weighted average ROE was 2.18%, down 0.54 percentage points year-over-year.

• Gross margin and other profitability ratios not explicitly disclosed.